LASMIDITAN: A NEW DRUG FOR ACUTE MIGRAINE

In related to the increased risk of cardio vascular (CV) diseases associated with migraine, there is a interest in the development of a new drug in the treatment of acute migraine which selectively act on non-vascular targets. Existing treatments are limited due to contra indications, or patient avoidance of side effects. This analysis show that 5-HT1F agonist have shown improved results in the treatment of migraine head ache. Also indicated the safety and efficacy of oral lasmiditan, a selective serotonin 5-hydroxytryptamine 1F receptor agonist in the migraine treatment. Research suggests that lasmiditan lacks vasoconstrictive properties and may be a safe and effective treatment in patient’s refractory to the acute migraine.